Clinical trials: Peripheral Vascular Diseases
Peripheral Arterial Disease
Clinical Study of Endovascular Interventional Surgical Instrument Control System and Related Consumables in Lower Extremity Arteriosclerosis Occlusive Lumen
This trial was a prospective, multicenter, single-group design. To undergo endovascular treatment of lower extremity arteriosclerosis obliterans After the subjects were selected and enrolled, the surgeons used the endovascular…
- Trial name
- NCT05625711
- Testing
- The endovascular interventional surgical instrument control system
- Volunteers
- 260 people
- Sponsor
- Shanghai Operation Robot Co., Ltd.
Peripheral Arterial Disease, Arterio-venous Fistula
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
The objective of this registry is to collect observational data under local standard of care and evaluate safety and performance of the Serranator® Alto in treatment of peripheral artery disease (PAD), or dysfunctional native or…
- Conditions
- Peripheral Arterial Disease, Arterio-venous Fistula, Arteriovenous Graft
- Trial name
- NCT03538392
- Testing
- Serranator® Alto
- Sponsor
- Cagent Vascular LLC
Multiple Myeloma, Myelodysplastic Syndromes
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in all patients who are treated with it under the actual condition of use pursuant to the conditions of approval. 1.
- Trial name
- NCT02921802
- Where
- Japan
- Volunteers
- 4,626 people
- Sponsor
- Celgene
Peripheral Arterial Disease
Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
This is a prospective, multi-center, pilot feasibility study to document the effects of adventitial delivery of temsirolimus or temsirolimus with dexamethasone sodium phosphate injection, USP, after revascularization of…
- Trial name
- TAP-DANCE (NCT03942601)
- Testing
- Temsirolimus, Temsirolimus and dexamethasone sodium phosphate
- Where
- 11 sites in United States
- Volunteers
- 10 people
- Sponsor
- Mercator MedSystems, Inc.
Systemic Sclerosis
A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).
- Trial name
- NCT04744207
- Testing
- GS-248
- Where
- 12 sites in Belgium, Netherlands and 2 more
- Volunteers
- 94 people
- Sponsor
- Gesynta Pharma AB
PAD - Peripheral Arterial Disease, PAD
Tack Optimized Balloon Angioplasty Post-Market Study
The objective of this study is to obtain outcomes following dissection repair with the Tack Endovascular System in a broad population of patients undergoing endovascular treatment of lesions within the superficial femoral…
- Conditions
- PAD - Peripheral Arterial Disease, PAD, Dissection, Arterial Dissection
- Trial name
- TOBA PMS (NCT05361967)
- Testing
- The Tack Endovascular System
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- Spectranetics Corporation
Raynaud's Disease, Peripheral Vascular Disease
PF-00489791 For The Treatment Of Raynaud's
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
- Trial name
- NCT01090492
- Testing
- PF-00489791
- Where
- 55 sites in United States, Canada and 9 more
- Volunteers
- 243 people
- Sponsor
- Pfizer
Peripheral Arterial Occlusive Disease
Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes
The purpose of this study is to evaluate acute and long term clinical and economic outcomes of endovascular procedures to treat Peripheral Arterial Disease (PAD).
- Trial name
- LIBERTY (NCT01855412)
- Testing
- PAD endovascular treatments
- Where
- 52 sites in United States
- Volunteers
- 1,204 people
- Sponsor
- Abbott Medical Devices
Critical Limb Ischemia, Critical Lower Limb Ischemia
PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
The LimFlow System is intended for endovascular, minimally invasive procedures in patients who have a clinical diagnosis of chronic limb-threatening ischemia and who have been determined to have no surgical or endovascular…
- Conditions
- Critical Limb Ischemia, Critical Lower Limb Ischemia, Peripheral Artery Disease, Peripheral Arterial Disease
- Trial name
- PROMISE (NCT03970538)
- Testing
- LimFlow System
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 105 people
- Sponsor
- LimFlow, Inc.
Peripheral Arterial Disease, Peripheral Vascular Disease
Zilver® PTX™ Global Registry
The Zilver PTX Registry Study is a prospective, non-randomized, open-label, multicenter single-arm study enrolling patients in Europe, Asia, and North America with de novo or restenotic (including in-stent restenosis) lesions of…
- Trial name
- NCT01094678
- Testing
- Zilver® PTX™ Stent
- Where
- 4 sites in Germany, Italy
- Volunteers
- 788 people
- Sponsor
- Cook Group Incorporated
Peripheral Arterial Disease
Zilver PTX Drug-Eluting Peripheral Stent Study
This randomized, post-market clinical study is intended to evaluate the delivery and deployment of longer Zilver PTX stents (≥ 100 mm) compared to shorter Zilver PTX stents (≤80 mm) for treatment of lesions of the above-the-knee…
- Trial name
- NCT01348425
- Testing
- Longer Zilver PTX Stents, Shorter Zilver PTX Stents
- Where
- 4 sites in Germany, Switzerland
- Volunteers
- 45 people
- Sponsor
- Cook Group Incorporated
Peripheral Arterial Diseases
The Jetstream (JET) Post-market Registry
The scope of the JET registry to observe long term treatment effects of Jetstream Navitus on various lesions types/morphologies.
- Trial name
- JET (NCT01436435)
- Testing
- Jetstream Atherectomy System
- Where
- 11 sites in United States
- Volunteers
- 241 people
- Sponsor
- Boston Scientific Corporation
Peripheral Arterial Occlusive Disease, Critical Limb Ischemia
Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)
The goal of this Phase 0 clinical trial is to evaluate safety and biodistribution of [89Zr]Zr-DFO-APAC in patients with peripheral arterial occlusive disease / critical limb ischemia (PAOD/CLI) and healthy volunteers.
- Trial name
- CHASE (NCT06204237)
- Testing
- [89Zr]Zr-DFO-APAC, PET/CT scan
- Where
- Netherlands
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Aplagon Oy
Primary Erythromelalgia, Inherited Erythromelalgia
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
This is a Phase 2a single-center, randomized, double-blind, Placebo-controlled, parallel group study with XPF-002 applied twice daily over 14 or 21 days in patients with Primary/Inherited Erythromelalgia (IEM).
- Trial name
- NCT01486446
- Testing
- XPF-002
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Critical Limb Ischemia
Stellarex DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries
The purpose is to demonstrate the safety and effectiveness of the Stellarex DCB for the treatment of stenosis or occlusions of below-the-knee arteries.
- Trial name
- ILLUMENATE-BTK (NCT03175744)
- Testing
- Stellarex DCB, PTA Catheter
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 82 people
- Sponsor
- Spectranetics Corporation
Peripheral Arterial Occlusive Disease
Study Comparing Synthetic Vascular Grafts in Patients With Peripheral Artery Disease (PAD) Who Require Artery Bypass.
To demonstrate the patency and safety of vascular grafts: EXXCEL and FUSION Bioline.
- Trial name
- FINEST (NCT01113892)
- Testing
- vascular grafts
- Where
- 25 sites in United States, Czechia and 1 more
- Volunteers
- 207 people
- Sponsor
- Maquet Cardiovascular
Refractory Cancer, Refractory Neoplasm
9-ING-41 in Pediatric Patients With Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor
- Trial name
- NCT04239092
- Testing
- 9-ING-41, Irinotecan, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Actuate Therapeutics Inc.
Multiple Myeloma
T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant
Patients will have immune cells collected and then expanded outside of the body. Patients will undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation.
- Trial name
- NCT00048464
- Testing
- Infusion of Activated & Expanded Autologous T Cells
- Where
- 6 sites in United States
- Volunteers
- 35 people
- Sponsor
- Xcyte Therapies
Peripheral Arterial Disease, Peripheral Vascular Diseases
Safety and Efficacy of Autologous Concentrated Bone Marrow Aspirate for Critical Limb Ischemia - Continued Access
This study will continue to evaluate the performance of the MarrowStim™ PAD Kit to treat subjects with critical limb ischemia (CLI) caused by severe PAD.
- Conditions
- Peripheral Arterial Disease, Peripheral Vascular Diseases, Critical Limb Ischemia
- Trial name
- MOBILE-CA (NCT02474121)
- Testing
- Bone marrow concentration device
- Where
- 9 sites in United States
- Sponsor
- Zimmer Biomet
Peripheral Arterial Disease (PAD)
Evaluation of WIRION™ EPS in Lower Extremities Arteries
Demonstrate the safety and performance of the WIRION™ EPS in subjects undergoing lower extremity atherectomy for the treatment of Peripheral Arterial Disease (PAD)
- Trial name
- WISE-LE (NCT02780349)
- Testing
- WIRION
- Where
- 10 sites in United States, Germany
- Volunteers
- 103 people
- Sponsor
- Gardia Medical